Therapeutic Asset Ratings
19,639 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
METHOTREXATE
Congenital Amegakaryocytic Thrombocytopenia
Fred Hutchinson Cancer Center
P2
BB
(66)
METHOTREXATE
Diamond-Blackfan Anemia
Fred Hutchinson Cancer Center
P2
BB
(66)
METHOTREXATE
Hematopoietic And Lymphoid Cell Neoplasm
Therapeutic Advances in Childhood Leukemia Consortium
P2
BB
(66)
Monomethyl Fumarate
Hematologic Diseases
University of Michigan Rogel Cancer Center
P2
BB
(66)
Neflamapimod
Lewy Body Dementia
EIP Pharma Inc
P2
BB
(66)
Niraparib
Stage IV Pancreatic Cancer AJCC v8
OHSU Knight Cancer Institute
P2
BB
(66)
Nivolumab
Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
P2
BB
(66)
Nivolumab
Refractory Mantle Cell Lymphoma
University of Washington
P2
BB
(66)
Nk Cell
Acute Myeloid Leukemia
Hospital de Clinicas de Porto Alegre
P2
BB
(66)
Olaparib
Exocrine Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
BB
(66)
Olaparib
Unresectable Pancreatic Carcinoma
National Cancer Institute (NCI)
P2
BB
(66)
Palbociclib
Hormone Receptor Positive Tumor
Relay Therapeutics, Inc.
P2
BB
(66)
PANITUMUMAB
Breast Cancer
National Cancer Institute (NCI)
P2
BB
(66)
Pelareorep
Breast Cancer
Adlai Nortye Biopharma Co., Ltd.
P2
BB
(66)
Pembrolizumab
Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
P2
BB
(66)
Pembrolizumab
B-Cell Non-Hodgkin Lymphoma
Rita Assi
P2
BB
(66)
Pembrolizumab
Diffuse Large B-Cell Lymphoma
Roswell Park Cancer Institute
P2
BB
(66)
Pembrolizumab
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
BB
(66)
Pembrolizumab
Metastatic Pancreatic Adenocarcinoma
Mayo Clinic
P2
BB
(66)
Pembrolizumab
Mycosis Fungoides
Sorrento Therapeutics, Inc.
P2
BB
(66)
Pembrolizumab
Non-Hodgkin Lymphoma
Seda S. Tolu
P2
BB
(66)
Pembrolizumab
Malignant Pancreatic Neoplasm
Essen Biotech
P2
BB
(66)
Pembrolizumab
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Seda S. Tolu
P2
BB
(66)
Pembrolizumab
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Seda S. Tolu
P2
BB
(66)
Pembrolizumab
Urinary Bladder Neoplasm
Eli Lilly and Company
P2
BB
(66)
Showing 676 to 700 of 19,639 assets
Previous
Page 28 of 786
Next